Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.

Nammalwar B, Bunce RA, Berlin KD, Benbrook DM, Toal C.

Eur J Med Chem. 2019 May 15;170:16-27. doi: 10.1016/j.ejmech.2019.03.010. Epub 2019 Mar 7.

PMID:
30878829
2.

Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.

Watts FM Jr, Pouland T, Bunce RA, Berlin KD, Benbrook DM, Mashayekhi M, Bhandari D, Zhou D.

Eur J Med Chem. 2018 Oct 5;158:720-732. doi: 10.1016/j.ejmech.2018.09.036. Epub 2018 Sep 14.

PMID:
30245396
3.

Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice.

Mahjabeen S, Hatipoglu MK, Benbrook DM, Garcia-Contreras L.

J Pharm Sci. 2018 Dec;107(12):3179-3186. doi: 10.1016/j.xphs.2018.08.024. Epub 2018 Sep 6.

PMID:
30196041
4.

Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration.

Mahjabeen S, Hatipoglu MK, Benbrook DM, Kosanke SD, Garcia-Contreras D, Garcia-Contreras L.

Eur J Pharm Biopharm. 2018 Sep;130:272-280. doi: 10.1016/j.ejpb.2018.07.004. Epub 2018 Jul 4.

5.

Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity.

Ramraj SK, Smith KM, Janakiram NB, Toal C, Raman A, Benbrook DM.

Tissue Cell. 2018 Jun;52:57-64. doi: 10.1016/j.tice.2018.04.001. Epub 2018 Apr 4.

6.

Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors.

Carlson BW, Craft MA, Carlson JR, Razaq W, Deardeuff KK, Benbrook DM.

Geroscience. 2018 Jun;40(3):325-336. doi: 10.1007/s11357-018-0025-z. Epub 2018 May 26.

7.

Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.

Sharma A, Benbrook DM, Woo S.

PLoS One. 2018 Apr 10;13(4):e0194046. doi: 10.1371/journal.pone.0194046. eCollection 2018.

8.

Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.

Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG.

Cancer Lett. 2018 Jul 1;425:174-182. doi: 10.1016/j.canlet.2018.03.027. Epub 2018 Mar 21.

PMID:
29574275
9.

Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV.

Invest New Drugs. 2018 Aug;36(4):561-570. doi: 10.1007/s10637-017-0550-0. Epub 2017 Dec 22.

10.

Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia.

Mahjabeen S, Hatipoglu MK, Chandra V, Benbrook DM, Garcia-Contreras L.

J Pharm Sci. 2018 Feb;107(2):638-646. doi: 10.1016/j.xphs.2017.09.018. Epub 2017 Oct 6.

11.

Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.

Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV.

Immunology. 2017 Sep;152(1):36-51. doi: 10.1111/imm.12746. Epub 2017 May 29.

12.

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D.

Gynecol Oncol. 2017 May;145(2):291-297. doi: 10.1016/j.ygyno.2017.02.040. Epub 2017 Mar 10.

13.

Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.

Griffith J, Andrade D, Mehta M, Berry W, Benbrook DM, Aravindan N, Herman TS, Ramesh R, Munshi A.

Oncol Rep. 2017 Apr;37(4):2382-2390. doi: 10.3892/or.2017.5478. Epub 2017 Feb 28.

14.
15.

The pro-inflammatory effect of obesity on high grade serous ovarian cancer.

Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM.

Gynecol Oncol. 2016 Oct;143(1):40-45. doi: 10.1016/j.ygyno.2016.07.103. Epub 2016 Jul 15.

PMID:
27423378
16.

Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules.

Walgama C, Al Mubarak ZH, Zhang B, Akinwale M, Pathiranage A, Deng J, Berlin KD, Benbrook DM, Krishnan S.

Anal Chem. 2016 Mar 15;88(6):3130-5. doi: 10.1021/acs.analchem.5b04234. Epub 2016 Feb 29.

PMID:
26886845
17.

Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers.

Okon IS, Ding Y, Coughlan KA, Wang Q, Song P, Benbrook DM, Zou MH.

Oncotarget. 2016 Feb 16;7(7):7970-8. doi: 10.18632/oncotarget.6699.

18.

Therapeutic options for management of endometrial hyperplasia.

Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R.

J Gynecol Oncol. 2016 Jan;27(1):e8. doi: 10.3802/jgo.2016.27.e8. Epub 2015 Dec 1. Review.

19.

Targeting autophagy in cancer management - strategies and developments.

Ozpolat B, Benbrook DM.

Cancer Manag Res. 2015 Sep 11;7:291-9. doi: 10.2147/CMAR.S34859. eCollection 2015. Review.

20.

Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line.

Gnanasekaran KK, Benbrook DM, Nammalwar B, Thavathiru E, Bunce RA, Berlin KD.

Eur J Med Chem. 2015;96:209-17. doi: 10.1016/j.ejmech.2015.03.070. Epub 2015 Apr 4.

PMID:
25880346
21.

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM.

Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11.

22.

History of retinoic acid receptors.

Benbrook DM, Chambon P, Rochette-Egly C, Asson-Batres MA.

Subcell Biochem. 2014;70:1-20. doi: 10.1007/978-94-017-9050-5_1. Review.

PMID:
24962878
23.

Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.

Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, Nelson T, McMeekin DS, Moore KN.

Gynecol Oncol. 2014 Apr;133(1):11-5. doi: 10.1016/j.ygyno.2014.01.031.

PMID:
24680585
24.

Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures.

Bishop EA, Lightfoot S, Thavathiru E, Benbrook DM.

Cancer Invest. 2014 Mar;32(3):63-70. doi: 10.3109/07357907.2013.877479.

PMID:
24499106
25.

SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.

Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, Berlin KD.

Invest New Drugs. 2014 Jun;32(3):412-23. doi: 10.1007/s10637-013-0041-x. Epub 2013 Nov 20.

26.

Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.

Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV.

Cancer Prev Res (Phila). 2013 Sep;6(9):908-16. doi: 10.1158/1940-6207.CAPR-13-0171. Epub 2013 Jul 12.

27.

The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.

Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.

Gynecol Oncol. 2013 Aug;130(2):377-82. doi: 10.1016/j.ygyno.2013.04.054. Epub 2013 Apr 28.

PMID:
23632208
28.

Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis.

Benbrook DM, Long A.

Exp Oncol. 2012 Oct;34(3):286-97. Review.

PMID:
23070014
29.

Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs.

Kabirov KK, Kapetanovic IM, Benbrook DM, Dinger N, Mankovskaya I, Zakharov A, Detrisac C, Pereira M, Martín-Jiménez T, Onua E, Banerjee A, van Breemen RB, Nikolić D, Chen L, Lyubimov AV.

Drug Chem Toxicol. 2013 Jul;36(3):284-95. doi: 10.3109/01480545.2012.710632. Epub 2012 Sep 5.

PMID:
22947079
30.

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM.

Gynecol Oncol. 2012 Nov;127(2):356-61. doi: 10.1016/j.ygyno.2012.07.095. Epub 2012 Jul 14.

PMID:
22796461
31.

Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.

Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM.

Mutat Res. 2012 Jul 4;746(1):78-88. doi: 10.1016/j.mrgentox.2012.03.009. Epub 2012 Apr 10.

32.

Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.

Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L.

Oncogene. 2012 May 31;31(22):2725-37. doi: 10.1038/onc.2011.455. Epub 2011 Oct 17.

PMID:
22002305
33.

Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline).

Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ.

Cancer Lett. 2011 Dec 15;312(1):11-7. doi: 10.1016/j.canlet.2011.06.032. Epub 2011 Jul 6.

34.

Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms.

Zheng J, Benbrook DM, Yu H, Ding WQ.

Anticancer Res. 2011 Sep;31(9):2739-47.

PMID:
21868515
35.

Internal standard-based analysis of microarray data2--analysis of functional associations between HVE-genes.

Dozmorov IM, Jarvis J, Saban R, Benbrook DM, Wakeland E, Aksentijevich I, Ryan J, Chiorazzi N, Guthridge JM, Drewe E, Tighe PJ, Centola M, Lefkovits I.

Nucleic Acids Res. 2011 Oct;39(18):7881-99. doi: 10.1093/nar/gkr503. Epub 2011 Jun 28.

36.

The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis.

Benbrook DM, Masamha CP.

Curr Cancer Drug Targets. 2011 Jun;11(5):586-99. Review.

PMID:
21486222
37.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.

Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.

38.
39.

N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death.

Zheng J, Lou JR, Zhang XX, Benbrook DM, Hanigan MH, Lind SE, Ding WQ.

Cancer Lett. 2010 Dec 8;298(2):186-94. doi: 10.1016/j.canlet.2010.07.003. Epub 2010 Jul 27.

40.

NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.

Chengedza S, Benbrook DM.

Anticancer Drugs. 2010 Mar;21(3):297-305. doi: 10.1097/CAD.0b013e3283350e43.

41.

Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.

Moxley KM, Chengedza S, Benbrook DM.

Gynecol Oncol. 2009 Dec;115(3):438-42. doi: 10.1016/j.ygyno.2009.09.007. Epub 2009 Oct 4. Erratum in: Gynecol Oncol. 2010 Jun;117(3):510. Benbrook, Doris Mangiaracina [added].

42.

Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.

Masamha CP, Benbrook DM.

Cancer Res. 2009 Aug 15;69(16):6565-72. doi: 10.1158/0008-5472.CAN-09-0913. Epub 2009 Jul 28.

43.

Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling.

Tuller ER, Beavers CT, Lou JR, Ihnat MA, Benbrook DM, Ding WQ.

Mol Pharmacol. 2009 Sep;76(3):588-95. doi: 10.1124/mol.109.057430. Epub 2009 Jun 15.

PMID:
19528198
44.

PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells.

Tuller ER, Brock AL, Yu H, Lou JR, Benbrook DM, Ding WQ.

Biochem Pharmacol. 2009 May 1;77(9):1480-6. doi: 10.1016/j.bcp.2009.02.002. Epub 2009 Feb 13.

PMID:
19426685
45.

Development of flexible-heteroarotinoids for kidney cancer.

Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM.

Mol Cancer Ther. 2009 May;8(5):1227-38. doi: 10.1158/1535-7163.MCT-08-1069. Epub 2009 May 5.

46.

Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.

Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun SY.

Mol Cancer Ther. 2008 Nov;7(11):3556-65. doi: 10.1158/1535-7163.MCT-08-0648.

47.

Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry.

Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK.

Rapid Commun Mass Spectrom. 2008 Nov;22(21):3371-81. doi: 10.1002/rcm.3744.

PMID:
18837006
48.

Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM.

Invest New Drugs. 2009 Aug;27(4):304-18. doi: 10.1007/s10637-008-9175-7. Epub 2008 Sep 18.

49.

CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.

Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY.

Cancer Res. 2008 Jul 1;68(13):5335-44. doi: 10.1158/0008-5472.CAN-07-6209.

50.

Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc.

Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD.

Cancer Res. 2008 Mar 15;68(6):1636-46. doi: 10.1158/0008-5472.CAN-07-2345. Erratum in: Cancer Res. 2008 Apr 15;68(8):3076.

Supplemental Content

Loading ...
Support Center